ovel use of TXA to reduce the need for nasal packing in epistaxis

Not Applicable

Completed

• Conditions: Epistaxis; Signs and Symptoms

• Registration Number: ISRCTN34153772
• Lead Sponsor: Royal Devon and Exeter NHS Foundation Trust

Brief Summary

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30772866 protocol 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33612282/ (added 06/07/2021)

Detailed Description

Not available

Study Timeline

• Study Start: 2017-06-01
• Study Completion: 2019-06-30
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 496

Inclusion Criteria

1. Aged 18 or over, any gender
2. Presenting to the ED with spontaneous, atraumatic epistaxis, unresolved with simple first aid and standard initial therapy

Exclusion Criteria

1. Clinical evidence of shock, as determined by the treating clinician, or requirement for resuscitation (including but not limited to systolic BP< 90 mmHg).
2. Known allergy to TXA
3. Lacking capacity
4. Unwilling to give consent
5. No telephone or unwilling to be contacted by telephone
6. Known paranasal, nasopharyngeal or nasal cavity malignancy
7. Pregnancy
8. Sent to ED for specialist ENT treatment
9. Already undergone pre-hospital nasal packing
10. Prior participation in the study (i.e. received allocated treatment)
11. Prisoners
12. Epistaxis caused by trauma (excluding simple nose picking)
13. Known haemophilia

Study & Design

• Study Type: Interventional
• Study Design: Not specified